company background image
PEB

Pacific EdgeNZSE:PEB Stock Report

Market Cap

NZ$1.1b

7D

-1.4%

1Y

89.2%

Updated

18 Oct, 2021

Data

Company Financials +
PEB fundamental analysis
Snowflake Score
Valuation0/6
Future Growth6/6
Past Performance0/6
Financial Health6/6
Dividends0/6

PEB Overview

Pacific Edge Limited, a cancer diagnostic company, researches, develops, and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand, the United States, Australia, Singapore, and internationally.

Pacific Edge Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Pacific Edge
Historical stock prices
Current Share PriceNZ$1.40
52 Week HighNZ$0.68
52 Week LowNZ$1.59
Beta0.58
1 Month Change-6.04%
3 Month Change15.70%
1 Year Change89.19%
3 Year Change221.84%
5 Year Change191.67%
Change since IPO700.01%

Recent News & Updates

Jun 05
We're Hopeful That Pacific Edge (NZSE:PEB) Will Use Its Cash Wisely

We're Hopeful That Pacific Edge (NZSE:PEB) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, Pacific Edge...

May 14
Pacific Edge Limited (NZSE:PEB): Are Analysts Optimistic?

Pacific Edge Limited (NZSE:PEB): Are Analysts Optimistic?

We feel now is a pretty good time to analyse Pacific Edge Limited's ( NZSE:PEB ) business as it appears the company may...

Shareholder Returns

PEBNZ BiotechsNZ Market
7D-1.4%2.2%-0.5%
1Y89.2%1.8%2.2%

Return vs Industry: PEB exceeded the NZ Biotechs industry which returned 1.8% over the past year.

Return vs Market: PEB exceeded the NZ Market which returned 2.2% over the past year.

Price Volatility

Is PEB's price volatile compared to industry and market?
PEB volatility
PEB Beta0.58
Industry Beta1.52
Market Beta1

Stable Share Price: PEB is more volatile than 75% of NZ stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: PEB's weekly volatility (5%) has been stable over the past year, but is still higher than 75% of NZ stocks.

About the Company

FoundedEmployeesCEOWebsite
2001n/aDave Darlinghttps://www.pacificedgedx.com

Pacific Edge Limited, a cancer diagnostic company, researches, develops, and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand, the United States, Australia, Singapore, and internationally. It operates in two segments, Commercial and Research. The company offers Cxbladder, a genomic urine tests for the detection and management of bladder cancer.

Pacific Edge Fundamentals Summary

How do Pacific Edge's earnings and revenue compare to its market cap?
PEB fundamental statistics
Market CapNZ$1.09b
Earnings (TTM)-NZ$14.22m
Revenue (TTM)NZ$8.98m

123.6x

P/S Ratio

-78.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PEB income statement (TTM)
RevenueNZ$8.98m
Cost of RevenueNZ$5.47m
Gross ProfitNZ$3.51m
ExpensesNZ$17.73m
Earnings-NZ$14.22m

Last Reported Earnings

Mar 31, 2021

Next Earnings Date

Nov 26, 2021

Earnings per share (EPS)-0.018
Gross Margin39.10%
Net Profit Margin-158.47%
Debt/Equity Ratio0%

How did PEB perform over the long term?

See historical performance and comparison

Valuation

Is Pacific Edge undervalued compared to its fair value and its price relative to the market?

44.15x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate PEB's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate PEB's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: PEB is unprofitable, so we can't compare its PE Ratio to the Global Biotechs industry average.

PE vs Market: PEB is unprofitable, so we can't compare its PE Ratio to the NZ market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PEB's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PEB is overvalued based on its PB Ratio (44.2x) compared to the XO Biotechs industry average (5.1x).


Future Growth

How is Pacific Edge forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

85.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PEB is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.1%).

Earnings vs Market: PEB is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: PEB's is expected to become profitable in the next 3 years.

Revenue vs Market: PEB's revenue (58.9% per year) is forecast to grow faster than the NZ market (5.2% per year).

High Growth Revenue: PEB's revenue (58.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: PEB's Return on Equity is forecast to be very high in 3 years time (53.2%).


Past Performance

How has Pacific Edge performed over the past 5 years?

4.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PEB is currently unprofitable.

Growing Profit Margin: PEB is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: PEB is unprofitable, but has reduced losses over the past 5 years at a rate of 4% per year.

Accelerating Growth: Unable to compare PEB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PEB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (46.5%).


Return on Equity

High ROE: PEB has a negative Return on Equity (-56.65%), as it is currently unprofitable.


Financial Health

How is Pacific Edge's financial position?


Financial Position Analysis

Short Term Liabilities: PEB's short term assets (NZ$27.3M) exceed its short term liabilities (NZ$4.3M).

Long Term Liabilities: PEB's short term assets (NZ$27.3M) exceed its long term liabilities (NZ$1.8M).


Debt to Equity History and Analysis

Debt Level: PEB is debt free.

Reducing Debt: PEB had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PEB has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: PEB has sufficient cash runway for 1.5 years if free cash flow continues to grow at historical rates of 0.7% each year.


Dividend

What is Pacific Edge current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate PEB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PEB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PEB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PEB's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PEB's dividend in 3 years as they are not forecast to pay a notable one for the NZ market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Dave Darling

17.92yrs

Tenure

Mr. David Darling, also known as Dave has been the Chief Executive Officer at Pacific Edge Limited (previously known as Pacific Edge Biotechnology Ltd.) since November 2003 and serves as its Managing direc...


Leadership Team

Experienced Management: PEB's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

Experienced Board: PEB's board of directors are considered experienced (7.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.3%.


Top Shareholders

Company Information

Pacific Edge Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Pacific Edge Limited
  • Ticker: PEB
  • Exchange: NZSE
  • Founded: 2001
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: NZ$1.092b
  • Shares outstanding: 791.65m
  • Website: https://www.pacificedgedx.com

Location

  • Pacific Edge Limited
  • Centre for Innovation
  • 87 St David Street
  • Dunedin
  • 9016
  • New Zealand

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/18 06:01
End of Day Share Price2021/10/18 00:00
Earnings2021/03/31
Annual Earnings2021/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.